Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Primary immunodeficiency modeling with induced pluripotent stem cells

Primary immunodeficiency modeling with induced pluripotent stem cells Primary immunodeficiency modeling with induced pluripotent stem cells a,b c,d Itai M. Pessach and Luigi D. Notarangelo Department of Pediatric Critical Care, Edmond and Purpose of review Lily Safra Children’s Hospital, Sheba Medical Center, b The study of primary immunodeficiencies (PIDs) has largely been based on animal The Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer, Israel, Division of models, in-vitro assays, and the study of patient-derived tissue. Although very important, Immunology, Children’s Hospital, Harvard Medical these approaches carry significant limitations including limited access to disease- School and The Manton Center for Orphan Disease Research, Children’s Hospital, Boston, Massachusetts, specific tissue. Here, we focus on a novel approach based on the use of patient-derived USA induced pluripotent stem cells (iPSCs) that may overcome some of the inherent Correspondence to Itai M. Pessach, MD, PhD, limitations of the classical approaches to the study of PIDs. Department of Pediatric Critical Care, Edmond and Lily Recent findings Safra Children’s Hospital, Tel-Hashomer 52621, Israel E-mail: Itai.Pessach@sheba.health.gov.il Recent advances have paved the way to disease modeling by iPSCs in many fields including the study of PIDs. However, significant challenges in the use of iPSCs for Current Opinion in Allergy and Clinical Immunology 2011, 11:505–511 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy and Clinical Immunology Wolters Kluwer Health

Primary immunodeficiency modeling with induced pluripotent stem cells

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/primary-immunodeficiency-modeling-with-induced-pluripotent-stem-cells-icGcO8Uhac

References (49)

Copyright
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0b013e32834cb943
pmid
22001741
Publisher site
See Article on Publisher Site

Abstract

Primary immunodeficiency modeling with induced pluripotent stem cells a,b c,d Itai M. Pessach and Luigi D. Notarangelo Department of Pediatric Critical Care, Edmond and Purpose of review Lily Safra Children’s Hospital, Sheba Medical Center, b The study of primary immunodeficiencies (PIDs) has largely been based on animal The Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer, Israel, Division of models, in-vitro assays, and the study of patient-derived tissue. Although very important, Immunology, Children’s Hospital, Harvard Medical these approaches carry significant limitations including limited access to disease- School and The Manton Center for Orphan Disease Research, Children’s Hospital, Boston, Massachusetts, specific tissue. Here, we focus on a novel approach based on the use of patient-derived USA induced pluripotent stem cells (iPSCs) that may overcome some of the inherent Correspondence to Itai M. Pessach, MD, PhD, limitations of the classical approaches to the study of PIDs. Department of Pediatric Critical Care, Edmond and Lily Recent findings Safra Children’s Hospital, Tel-Hashomer 52621, Israel E-mail: Itai.Pessach@sheba.health.gov.il Recent advances have paved the way to disease modeling by iPSCs in many fields including the study of PIDs. However, significant challenges in the use of iPSCs for Current Opinion in Allergy and Clinical Immunology 2011, 11:505–511

Journal

Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health

Published: Dec 1, 2011

There are no references for this article.